


ASCO24

TOP TEN BY ONCOALERT

GI CANCER



OncoAlert³⁶⁰
Oncology For Colleagues By Colleagues

4000

A PHASE II/III STUDY OF PERI-OPERATIVE NIVOLUMAB (NIVO) AND IPILIMUMAB (IPI) IN PATIENTS (PTS) WITH LOCOREGIONAL ESOPHAGEAL (E) AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA (ECOG-ACRIN EA2174)

4005

NRG ONCOLOGY/RTOG 0848: RESULTS AFTER ADJUVANT CHEMOTHERAPY +/- CHEMORADIATION FOR PATIENTS WITH RESECTED PERIAMPULLARY PANCREATIC ADENOCARCINOMA (PA)

4003

A RANDOMIZED PHASE II STUDY OF GEMCITABINE AND NAB-PACLITAXEL COMPARED WITH 5-FLUOROURACIL, LEUCOVORIN, AND LIPOSOMAL IRINOTECAN IN OLDER PATIENTS WITH TREATMENT-NAÏVE METASTATIC PANCREATIC CANCER (GIANT): ECOG-ACRIN EA2186

4007

INTERNATIONAL, OPEN-LABEL PHASE 2 STUDY OF REGORAFENIB PLUS PEMBROLIZUMAB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH IMMUNE CHECKPOINT INHIBITORS

3509

FINAL RESULTS OF A PHASE 2 STUDY OF TUCATINIB AND TRASTUZUMAB FOR HER2-POSITIVE MCRC (MOUNTAINEER)

3503

NIVOLUMAB PLUS IPILIMUMAB (IPI) VS CHEMOTHERAPY AS FIRST-LINE (1L) TREATMENT FOR MICROSATELLITE INSTABILITY-HIGH/MISMATCH REPAIR-DEFICIENT (MSI-H/DMMR) METASTATIC COLORECTAL CANCER (MCRC): EXPANDED EFFICACY ANALYSIS FROM CHECKMATE 8HW.

LBA 3510

OS OF CODEBREAK 300 STUDY OF SOTORASIB PLUS PANITUMUMAB VS INVESTIGATOR'S CHOICE OF THERAPY FOR KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

LBA 3504

NEOPRISM-CRC: NEOADJUVANT PEMBROLIZUMAB STRATIFIED TO TUMOUR MUTATION BURDEN FOR HIGH RISK STAGE 2 OR STAGE 3 DEFICIENT-MMR/MSI-HIGH COLORECTAL CANCER.

LBA 4008

NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) VS LENVATINIB (LEN) OR SORAFENIB (SOR) AS FIRST-LINE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): FIRST RESULTS FROM CHECKMATE 9DW.

LBA 4001

-EFFECT OF CHEMOTHERAPY/TARGETED THERAPY ALONE VS. CHEMOTHERAPY/TARGETED THERAPY FOLLOWED BY RADICAL SURGICAL RESECTION ON SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH LIMITED-METASTATIC ADENOCARCINOMA OF THE STOMACH OR ESOPHAGOGASTRIC JUNCTION: THE IKF-575/RENAISSANCE PHASE III TRIAL.

Leads



Dr Ergün
Med Onc



Dr Can Guven
Med Onc



Dr Heinrich
Med Onc



Dr Morgan
Clin Onc

Faculty



Dr Westphalen
Med Onc